Dany's BienenWohl
oxalic acid dihydrate
Table of contents
Overview
Dany’s BienenWohl is a medicine used to treat varroosis in honey bee colonies. Varroosis is a disease of honey bees caused by infestation with a parasite called varroa mite (Varroa destructor). The varroa mite feeds on the haemolymph (blood) of adult bees and on brood (developing stages of the honey bee) resulting in harm and/or death of bees. The mite can also help spread viruses and bacteria. A significant mite infestation can lead to the collapse of a honey bee colony. Dany’s BienenWohl can only be used on colonies without brood and should be used as part of a wider management programme. If possible, the use of Dany’s BienenWohl should be alternated with another medicine that kills mites in a different way to reduce the chance of the mites developing resistance.
Dany’s BienenWohl contains the active substance oxalic acid. This medicine is the same as Oxybee, which is already authorised in the European Union (EU). The company that makes Oxybee has agreed that its scientific data can be used for Dany’s BienenWohl (‘informed consent’).
Authorisation details
Product details | |
---|---|
Name |
Dany's BienenWohl
|
Agency product number |
EMEA/V/C/004667
|
Active substance |
oxalic acid dihydrate
|
International non-proprietary name (INN) or common name |
oxalic acid dihydrate
|
Species |
Honey bees
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QP53AG03
|
Publication details | |
---|---|
Marketing-authorisation holder |
Dany Bienenwohl GmbH
|
Revision |
0
|
Date of issue of marketing authorisation valid throughout the European Union |
14/06/2018
|
Contact address |
Geyerspergerstrasse 27
80689 Munich Germany |
Product information
14/06/2018 Dany's BienenWohl - EMEA/V/C/004667 -
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Ectoparasiticides for topical use, incl. insecticides
-
Ectoparaciticides, insecticides and repellents
Therapeutic indication
For the treatment of varroosis (Varroa destructor) of honey bees (Apis mellifera) in brood-free colonies.